Design Therapeutics adds Dr. Heather Behanna and Deepa Prasad to its Board of Directors

– USA, CA –  Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced the appointments of industry veterans, Dr. Heather Behanna, Ph.D., principal of SR One, and Deepa Prasad, managing director of WestRiver Group, to its board of directors, effective June 15, 2021.

“We are delighted to further strengthen the Design team with the appointments of both Heather and Deepa to our board of directors, who bring a wealth of experience and insights in corporate and financial strategy and biotechnology company growth,” said CEO, Dr. João Siffert.

He added: “Over the course of 2021, we have continued to progress our pipeline of novel GeneTAC™ therapeutic candidates, and their expertise will be invaluable as we look to make the important transition to a clinical-stage company with the anticipated initiation of clinical development for our Friedreich ataxia program in the first half of next year.”

About Dr. Heather Behanna

Dr. Behanna currently serves as a principal at SR One Capital Management, concentrating on early-stage innovative therapeutic opportunities. Dr. Behanna is currently a board member of Second Genome and Entasis Therapeutics and a board observer of Dren Bio. Before SR One, she was with Sofinnova Investments, and before that, was an equity research analyst at Wedbush and JMP Securities, focused primarily on therapies for rare diseases.

Dr. Behanna was formerly a chemist at the Astellas Research Institute and adjunct faculty at the Feinberg Northwestern School of Medicine.

Dr. Behanna received her Ph.D. in chemistry at Northwestern University, MSc. in organic chemistry at the Weizmann Institute of Science, and B.S. from Tufts University.

“Friedreich ataxia is devastating, with no cure or approved disease-modifying treatment option today. I am highly encouraged by the opportunity enabled by Design’s approach to addressing the underlying cause of this disease,” said Dr. Behanna. “I look forward to working alongside the entire team to help guide the business strategy and development plans, so that we may potentially deliver the first treatment to increase endogenous frataxin for patients with Friedreich ataxia.”

About Deepa Prasad

Ms. Prasad currently serves as a managing director at WestRiver Group, where she leverages her more than 20 years of investing and operating experience to focus on investments in healthcare innovation across biotech and digital health, and artificial intelligence.

Before WRG, Ms. Prasad served as chief of staff at Blue Shield, regional vice president, and general manager for Optum, head of managed care at the California Hospital Association, and Coherus Biosciences where she led financial strategy and business development.

She began her career in investment banking working with biotech and pharma companies on private placements and buy-side and sell-side mergers and acquisitions. She currently serves on the Grant Funding Committee for UC Davis and as a charter member for TiE, a non-profit global network of entrepreneurs and venture capitalists. Ms. Prasad earned her bachelor’s degree in business administration at the University of California, Berkeley, and her M.B.A. from the Kellogg School of Management at Northwestern University with an emphasis in finance and health industry management.

“Design’s proprietary GeneTAC platform has a unique opportunity to address the root cause of genetic diseases driven by inherited nucleotide repeat expansions and make a significant impact on the lives of those affected,” said Deepa Prasad. “The team has made remarkable progress since its founding in 2017, and I am pleased to partner with the Design team and board of directors, so that we may bring forward a new class of small molecule therapeutics that provide a potentially disease-modifying therapy for these patients.”

About Design Therapeutics

Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene-targeted chimera small molecules. Our GeneTAC molecules are designed to either turn on or turn off a specific disease-causing gene to address the underlying cause of the disease. The company’s lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team